Cormorant Asset Management as of June 30, 2017
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 71 positions in its portfolio as reported in the June 2017 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Portola Pharmaceuticals | 8.4 | $51M | 900k | 56.17 | |
Theravance Biopharma (TBPH) | 6.3 | $38M | 950k | 39.84 | |
Bluebird Bio (BLUE) | 4.8 | $29M | 275k | 105.05 | |
Quotient | 4.3 | $26M | 3.5M | 7.36 | |
Omeros Corporation (OMER) | 4.3 | $26M | 1.3M | 19.91 | |
Galapagos Nv- (GLPG) | 3.8 | $23M | 300k | 76.39 | |
Juno Therapeutics | 3.7 | $22M | 750k | 29.89 | |
Nevro (NVRO) | 3.3 | $20M | 270k | 74.43 | |
Aclaris Therapeutics (ACRS) | 3.2 | $20M | 720k | 27.12 | |
Anaptysbio Inc Common (ANAB) | 3.2 | $19M | 800k | 23.93 | |
Blueprint Medicines (BPMC) | 3.1 | $19M | 368k | 50.67 | |
Proteostasis Therapeutics In | 3.0 | $18M | 3.8M | 4.68 | |
Minerva Neurosciences | 2.9 | $18M | 2.0M | 8.85 | |
Clearside Biomedical (CLSD) | 2.9 | $18M | 1.9M | 9.11 | |
Eagle Pharmaceuticals (EGRX) | 2.6 | $16M | 200k | 78.89 | |
Ignyta | 2.6 | $16M | 1.5M | 10.35 | |
Myokardia | 2.2 | $13M | 1.0M | 13.10 | |
Gemphire Therapeutics | 2.0 | $12M | 953k | 12.89 | |
Neurocrine Biosciences (NBIX) | 1.9 | $12M | 250k | 46.00 | |
Alder Biopharmaceuticals | 1.7 | $10M | 900k | 11.45 | |
Alnylam Pharmaceuticals (ALNY) | 1.6 | $10M | 125k | 79.76 | |
Coherus Biosciences (CHRS) | 1.5 | $8.9M | 620k | 14.35 | |
G1 Therapeutics | 1.4 | $8.4M | 480k | 17.44 | |
Heron Therapeutics (HRTX) | 1.3 | $7.9M | 570k | 13.85 | |
Array BioPharma | 1.2 | $7.5M | 900k | 8.37 | |
Ardelyx (ARDX) | 1.2 | $7.3M | 1.4M | 5.10 | |
Audentes Therapeutics | 1.0 | $6.2M | 324k | 19.13 | |
Protagonist Therapeutics (PTGX) | 0.9 | $5.7M | 500k | 11.31 | |
Synergy Pharmaceuticals | 0.9 | $5.3M | 1.2M | 4.45 | |
Dex (DXCM) | 0.8 | $5.1M | 70k | 73.16 | |
Contrafect | 0.8 | $5.1M | 3.6M | 1.45 | |
Invuity | 0.8 | $5.1M | 700k | 7.25 | |
Jounce Therapeutics | 0.8 | $5.0M | 360k | 14.03 | |
Dermira | 0.8 | $5.0M | 170k | 29.14 | |
Syros Pharmaceuticals | 0.8 | $4.8M | 296k | 16.09 | |
Fulgent Genetics (FLGT) | 0.8 | $4.8M | 750k | 6.39 | |
Agenus | 0.8 | $4.7M | 1.2M | 3.91 | |
Agile Therapeutics | 0.8 | $4.7M | 1.3M | 3.75 | |
Intec Pharma | 0.8 | $4.6M | 810k | 5.70 | |
Rigel Pharmaceuticals | 0.7 | $4.2M | 1.5M | 2.73 | |
Curis | 0.6 | $3.8M | 2.0M | 1.89 | |
Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.6 | $3.8M | 300k | 12.51 | |
Wave Life Sciences (WVE) | 0.6 | $3.8M | 202k | 18.60 | |
Cytomx Therapeutics (CTMX) | 0.6 | $3.6M | 230k | 15.50 | |
Sangamo Biosciences (SGMO) | 0.6 | $3.5M | 400k | 8.80 | |
Sorrento Therapeutics (SRNE) | 0.6 | $3.4M | 1.7M | 2.00 | |
Immune Design | 0.5 | $3.3M | 337k | 9.75 | |
Lipocine | 0.5 | $3.0M | 742k | 4.02 | |
Advanced Accelerat spon ads each rep 2 ord | 0.5 | $2.9M | 75k | 39.04 | |
Trillium Therapeutics, Inc. Cmn | 0.4 | $2.6M | 600k | 4.40 | |
Abeona Therapeutics | 0.4 | $2.6M | 400k | 6.40 | |
Recro Pharma | 0.4 | $2.3M | 333k | 7.03 | |
Regenxbio Inc equity us cm (RGNX) | 0.4 | $2.4M | 120k | 19.75 | |
Ovid Therapeutics (OVID) | 0.4 | $2.3M | 224k | 10.49 | |
Acceleron Pharma | 0.4 | $2.3M | 75k | 30.39 | |
Pfenex | 0.4 | $2.3M | 575k | 4.01 | |
Zymeworks | 0.3 | $1.9M | 232k | 8.35 | |
Xencor (XNCR) | 0.3 | $1.6M | 75k | 21.11 | |
Aptose Biosciences | 0.2 | $1.2M | 991k | 1.23 | |
Portola Pharmaceuticals | 0.2 | $1.2M | 1.0k | 1160.00 | |
Myovant Sciences | 0.2 | $1.2M | 100k | 11.70 | |
Mersana Therapeutics (MRSN) | 0.2 | $1.1M | 80k | 13.97 | |
Oncobiologics | 0.2 | $1.0M | 1.0M | 1.01 | |
Abbvie | 0.2 | $939k | 6.1k | 153.93 | |
Htg Molecular Diagnostics | 0.1 | $541k | 204k | 2.66 | |
Threshold Pharmaceuticals | 0.1 | $351k | 900k | 0.39 | |
Neos Therapeutics | 0.1 | $369k | 51k | 7.29 | |
Cellectar Biosciences | 0.0 | $87k | 54k | 1.62 | |
Oncobiologics Inc *w exp 02/18/201 | 0.0 | $71k | 417k | 0.17 | |
Oncobiologics Inc *w exp 05/18/201 | 0.0 | $38k | 417k | 0.09 | |
Cellectar Biosciences Equity Warrants *w | 0.0 | $12k | 53k | 0.23 |